<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319214</url>
  </required_header>
  <id_info>
    <org_study_id>10-039-PSY</org_study_id>
    <nct_id>NCT01319214</nct_id>
  </id_info>
  <brief_title>Reducing Drug Craving Memories</brief_title>
  <official_title>Reconsolidation as a Treatment Target for Cocaine Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate the potential ability of Inderal (propranolol&#xD;
      hydrochloride) to diminish the reconsolidation of motivationally potent drug-related cues in&#xD;
      cocaine dependent participants. If effective in this laboratory model, Inderal may have&#xD;
      clinical efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report drug craving</measure>
    <time_frame>One day and one month post-treatment</time_frame>
    <description>One day and one month after the intervention, the investigators will measure drug craving using visual analog scales (VAS) and the Cocaine Craving Questionnaire (CCQ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug use</measure>
    <time_frame>One month after the intervention</time_frame>
    <description>One month after the intervention, participants will be interviewed about their drug and alcohol use</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cocaine Addiction</condition>
  <arm_group>
    <arm_group_label>Inderal, neutral cues</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inderal, drug cues</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, neutral cues</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, drug cues</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inderal</intervention_name>
    <description>Inderal vs. placebo will be administered with or without cocaine cues</description>
    <arm_group_label>Inderal, drug cues</arm_group_label>
    <arm_group_label>Inderal, neutral cues</arm_group_label>
    <arm_group_label>Placebo, drug cues</arm_group_label>
    <arm_group_label>Placebo, neutral cues</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60 psychotropic medication-free men or women (15 subjects x 4 groups) who have met&#xD;
             DSM-IV-TR diagnostic criteria for cocaine dependence for the past 6 months (age 18 -&#xD;
             50 years old);&#xD;
&#xD;
          -  Minimum of three days cocaine abstinent on study days;&#xD;
&#xD;
          -  Primary use of cocaine is intra-nasal or smoked crack&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical conditions that might be aggravated by participation in the study:&#xD;
&#xD;
               -  cardiovascular disorders that might be aggravated by participation in the study:&#xD;
                  hypotension (SBP: &lt; 100 mmHg), bradycardia (heart rate &lt; 60 /min), severe&#xD;
                  atrioventricular block (Type II or III), severe hypertension (SBP: &gt; 160 mmHg;&#xD;
                  DBP: &gt; 100 mmHg), myocardial infarction, history of chest pain and admission to&#xD;
                  ED for chest pain;&#xD;
&#xD;
               -  respiratory disorders: bronchial asthma and chronic obstructive pulmonary&#xD;
                  disease;&#xD;
&#xD;
               -  diabetic patients treated with insulin or oral hypoglycemic agents. Propranolol&#xD;
                  may mask the first signs of a developing hypoglycemia.&#xD;
&#xD;
          -  Seropositive pregnancy test&#xD;
&#xD;
          -  Comorbidity with current axis I psychiatric disorders other than anxiety, affective&#xD;
             and substance use disorders&#xD;
&#xD;
          -  Severe liver disfunction&#xD;
&#xD;
          -  Current or recent (&lt; 5 half lives) use of medications that may interact with Inderal&#xD;
             (see above)&#xD;
&#xD;
          -  Positive urine tox screen for barbiturates. Positive breath alcohol screen. {Note: all&#xD;
             urine tox screen results will be destroyed immediately after collection. The&#xD;
             information will not be stored}&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marco Leyton</name_title>
    <organization>MUHC</organization>
  </responsible_party>
  <keyword>cocaine addiction treatment craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

